- Home
- Supplements
- Strontium
- Osteoporosis
Strontium for Osteoporosis
Prescription strontium ranelate did reduce fractures in large trials, but it was withdrawn in Europe for raising heart attack risk — and over-the-counter strontium citrate has never been tested for fracture prevention. Much of the apparent bone-density benefit is a DEXA measurement artifact.
Overview
Verdict
The drug form worked but had cardiovascular harm; the supplement form is untested. DEXA improvements are largely an artifact.
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- Not recommended
- Expected timeframe
- Not applicable
Protocol
- form
- Not applicable
- duration
- Not applicable
- co factor
- The verdict is no, and this one is about harm rather than absence of benefit. Prescription strontium ranelate at 2 g/day did reduce vertebral and hip fracture in trials, but it was restricted and then withdrawn across Europe because of myocardial infarction, venous thromboembolism and severe hypersensitivity (DRESS) risk. Over-the-counter strontium citrate is a different, unstudied salt with no fracture data, and strontium falsely inflates bone density scan readings because it is denser than calcium, giving an illusion of improvement.
- titration
- Not applicable
- starting dose
- Not recommended
Evidence
What the studies say
Strontium ranelate for preventing and treating postmenopausal osteoporosis
O'Donnell S, Cranney A, Wells GA +2 more
Strontium ranelate reduces fractures but carries thromboembolic and gastrointestinal risks.
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study
Reginster JY, Seeman E, De Vernejoul MC +10 more
Strontium ranelate reduces nonvertebral fracture risk in postmenopausal osteoporosis.
Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate
Abrahamsen B, Grove EL, Vestergaard P
Cardiovascular safety concerns contributed to regulatory restriction of strontium ranelate.
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis
Meunier PJ, Roux C, Seeman E +10 more
Strontium ranelate reduces vertebral fracture risk in postmenopausal osteoporosis.
Safety
Caveats
Do not use strontium supplements for osteoporosis. The prescription form was withdrawn for cardiovascular harm, and the supplement form has no fracture-prevention evidence while still distorting DXA scans, which undermines monitoring of real treatment. Osteoporosis has effective, well-evidenced options: bisphosphonates, denosumab, and anabolic agents, alongside adequate calcium, vitamin D and resistance exercise. Strontium is contraindicated with a history of venous thromboembolism, ischaemic heart disease, stroke or uncontrolled hypertension, and it interferes with calcium absorption and binds tetracycline and quinolone antibiotics. Contraindicated in pregnancy and breastfeeding. Get a fracture risk assessment and a DXA scan instead.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.